Dry eye disease has become a public health issue, with increasing prevalence in the United States, where more than 16 million people are affected.
Nearly 50% of eyes with wet age-related macular degeneration (AMD) have stable or improved vision after long-term, 8-year pro re nata (PRN) treatment with ranibizumab, according to a group of U.K. clinicians.
This article was reviewed by Andrea A. Tooley, MD
This article was reviewed by Irmgard Behlau, MD
An internationally renowned working group of retina specialists, ocular imaging experts, and ocular pathologists have suggested standardizing definitions for age-related macular degeneration (AMD) and its subtypes.
Optometry Australia has developed an AMD chairside reference in consultation with a member-based working group comprised of experienced practitioners.
When considering accomplishments recorded in the arena of gene therapy, the “firsts” are impressive.
Findings from studies investigating the efficacy and safety of corneal collagen crosslinking (CXL) for keratoconus in paediatric-age patients and developmentally delayed adults and the consequences of leaving their ocular disease untreate